LungLife AI, INC Block listing Interim Review

RNS Number : 7676L

LungLife AI, INC

15 November 2024

 

LungLife AI, Inc.
(the "Company" or "LungLife")

 

Block Listing Six Monthly Return

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 

Name of applicant:		LungLife AI, Inc.
Name of scheme:		1.    2010 Stock Incentive Plan 2.    2020 Stock Incentive Plan 3.    2021 Omnibus Long-Term Incentive Plan
Number and class of securities originally admitted:		1,356,139 common shares of US $0.0001 each
Date of admission:		15 November 2021
Period of return:	From:	15 May 2024	To:	15 November 2024
Balance of unallotted securities under scheme(s) from previous return:		1.    475,583 2.    201,374 3.    673,990
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1.    NIL 2.    NIL 3.    NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		1.    NIL 2.    NIL 3.    NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1.    475,583 2.    201,374 3.    673,990
Total number of securities in issue at the end of the period		30,658,603

 

Name of contact:	David Anderson, Chief Financial Officer
Telephone number of contact:	[phone]

 

 

For further information please contact:

 

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	via [e-mail]
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Broker)	Tel: [phone]
Virginia Bull / Lydia Zychowska / Sara Wallace
Goodbody (Joint Broker)	Tel: [phone]
Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

 

Our Purpose is to be a driving force in the early detection to lung cancer.  And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BLRFLFIRLTLLLIS